What is stanozolol used for?

Stanozolol has historically been studied in medical contexts for conditions such as hereditary angioedema and for anabolic support physiology.

Is stanozolol the same as Winstrol?

Yes, Winstrol is the commonly known brand name for the compound Stanozolol.

Does stanozolol help build muscle?

Stanozolol is associated with anabolic activity that may support protein synthesis and lean muscle development.

How long does stanozolol stay active?

The duration of activity depends on the formulation, but injectable stanozolol may remain active in the body for several days.

What are the side effects of stanozolol?

Possible side effects include hormonal imbalance, acne, cholesterol changes, and other androgen related effects.

Stanozolol Injectable (CAS 10418-03-8)

Name: Stanozolol
Brand: Nova Techsciences
SKU: roxonova

Quick Facts

Form

Injectable solution

Strength

Stanozolol 50 mg/ml

Pack Size

10 ml multidose vial

Route

Intramuscular (IM) injection

Indication

ROXONOVA Stanozolol Injectable (CAS 10418-03-8)What is Stanozolol (CAS 10418-03-8)?Mechanism of ActionProtein synthesis and muscle tissue developmentNitrogen retention within muscle cellsIncreased strength and endurance environments

ROXONOVA Stanozolol Injectable (CAS 10418-03-8)

ROXONOVA Injectable by NovaTech Sciences contains pharmaceutical-grade Stanozolol (CAS 10418-03-8), a synthetic anabolic androgenic compound widely recognized for its association with strength development, lean muscle environments, and performance physiology. The compound is globally identified through CAS 10418-03-8, ensuring chemical authenticity, pharmaceutical traceability, and standardized compound identification across international pharmaceutical markets.

NovaTech Sciences manufactures Stanozolol CAS 10418-03-8 using advanced pharmaceutical technologies designed to maintain compound purity, sterile injectable formulation quality, and reliable global distribution.

What is Stanozolol (CAS 10418-03-8)?

Stanozolol, registered under CAS 10418-03-8, is a synthetic derivative of dihydrotestosterone (DHT). It is widely recognized for its anabolic properties and has historically been studied in medical and performance-related contexts.

The CAS registry number 10418-03-8 serves as the globally recognized chemical identifier for Stanozolol. This identifier ensures compound verification, regulatory documentation, and pharmaceutical transparency across manufacturing and distribution systems.

Stanozolol gained prominence in medical research for applications involving hereditary angioedema and conditions related to muscle preservation.

Mechanism of Action

Stanozolol CAS 10418-03-8 works by interacting with androgen receptors located throughout the body. Once administered, the compound influences several biological processes associated with anabolic signaling and metabolic activity.

Activation of androgen receptors contributes to

Protein synthesis and muscle tissue development

Nitrogen retention within muscle cells

Increased strength and endurance environments

Enhanced red blood cell production

Lean muscle preservation and metabolic efficiency

Because of its unique chemical structure, Stanozolol CAS 10418-03-8 is often associated with lean muscle development rather than water retention environments.

Key Features of Stanozolol CAS 10418-03-8

ROXONOVA injectable provides pharmaceutical-grade Stanozolol (CAS 10418-03-8) with several defining characteristics

Verified CAS 10418-03-8 compound identity

Association with lean muscle development environments

Support for strength and performance physiology

Recognized anabolic compound in research contexts

Pharmaceutical-grade sterile injectable manufacturing

Each production batch of Stanozolol CAS 10418-03-8 undergoes strict laboratory testing to verify compound identity, purity levels, and sterile pharmaceutical quality.

Pharmaceutical Manufacturing & Global Supply

NovaTech Sciences operates as a trusted manufacturer, supplier, and exporter of pharmaceutical-grade anabolic compounds for global healthcare markets. By specifying CAS 10418-03-8, ROXONOVA injectable maintains chemical authenticity and regulatory compliance.

Manufacturing protocols include

Raw material authentication

CAS-verified compound validation

Controlled sterile injectable production environments

Batch consistency and sterility testing

Export-compliant pharmaceutical packaging

These strict quality assurance systems ensure Stanozolol injectable formulations meet pharmaceutical distribution standards required by international partners.

Why Choose ROXONOVA by NovaTech Sciences?

NovaTech Sciences focuses on pharmaceutical precision, regulatory compliance, and consistent formulation quality. ROXONOVA containing Stanozolol CAS 10418-03-8 is manufactured using advanced pharmaceutical processes designed to maintain stable formulation performance.

Key advantages include

Pharmaceutical-grade sterile injectable standards

Verified CAS compound identification

Trusted global manufacturing reputation

Consistent batch-to-batch product quality

Reliable international export supply capability

Conclusion

For pharmaceutical distributors and healthcare suppliers seeking a dependable source of Stanozolol (CAS 10418-03-8), ROXONOVA Injectable by NovaTech Sciences offers verified compound identity, pharmaceutical manufacturing excellence, and reliable global supply. Supported by strict quality assurance protocols, Stanozolol CAS 10418-03-8 remains a recognized anabolic compound associated with lean muscle environments, strength development, and performance physiology.

Safety Information

Precautions

Use only under physician supervision.
Regular liver function and lipid profile monitoring is strongly advised.
Avoid alcohol consumption during use to reduce liver toxicity.
Monitor for joint discomfort as Stanozolol may cause joint dryness.
Long-term unsupervised use may suppress natural testosterone production.

Contraindications

Contraindicated in patients with liver disease, liver tumors, or severe hepatic dysfunction.
Not recommended for pregnant or breastfeeding women.
Avoid use in patients with prostate cancer or male breast cancer.
Not suitable for individuals with severe cardiovascular disease or uncontrolled cholesterol disorders.
Contraindicated in individuals with hypersensitivity to Stanozolol or formulation ingredients.

Stanozolol is a synthetic anabolic-androgenic compound identified by CAS Number 10418-03-8. It has the molecular formula C21H32N2O and is structurally derived from dihydrotestosterone. Nova Techsciences associates this compound with ROXONOVA, an injectable presentation listed at 50 mg/ml in a 10 ml multidose vial.

This compound page provides general chemical, quality and safety information. It should not replace approved prescribing information, a patient leaflet or an individual assessment by a qualified healthcare professional.

Stanozolol ROXONOVA Overview

Compound name: Stanozolol
CAS Number: 10418-03-8
Molecular formula: C21H32N2O
Listed strength: 50 mg/ml
Pharmaceutical form: Injectable formulation
Associated product: ROXONOVA
Brand: Nova Techsciences

The compound name, concentration and CAS number should remain consistent across the Nova Techsciences compound page, product page, packaging, structured data, Certificate of Analysis and batch-release documentation.

Chemical Identity and Quality Documentation

Stanozolol belongs to the androgenic and anabolic-steroid category. The CAS number provides a recognised identifier that distinguishes it from Methenolone, Testosterone, Trenbolone and other steroidal compounds with separate structures and safety profiles.

A responsible Stanozolol ROXONOVA profile should be supported by documented analytical and manufacturing controls. Relevant records may include raw-material authentication, active-compound assay, impurity analysis, reference-standard comparison, sterility assessment, particulate testing, stability evaluation and container-closure integrity.

Every production batch should have a unique identification number linked to its manufacturing history and laboratory-release results. Statements concerning purity, sterile quality, pharmaceutical standards or international compliance should only be published when current supporting evidence is available.

For audiences in the United Kingdom, Netherlands and other European markets, Nova Techsciences should clearly disclose the compound’s marketing-authorisation status, prescription classification, responsible organisation and adverse-event reporting process.

Important Safety Information

Stanozolol is not an ordinary wellness or nutritional compound. The NHS warns that anabolic-steroid misuse can cause serious cardiovascular, liver, kidney, hormonal, reproductive and psychological effects. It can also lead to dependence, while misuse during adolescence may restrict normal growth.

Stanozolol ROXONOVA should not be presented for self-medication, bodybuilding, sporting performance or use by minors. Dosage schedules, injection methods, cycles, combinations or strategies intended to reduce side effects should not be taken from unofficial sources.

Related Nova Techsciences Compounds

Methenolone Enanthate

Methenolone Enanthate is an esterified anabolic compound correctly identified by CAS Number 303-42-4. The primary Nova Techsciences record is corrected; any remaining content, metadata, packaging or laboratory documentation showing 303-40-4 should be updated.

Testosterone Suspension

Testosterone Suspension contains non-esterified testosterone, identified by CAS Number 58-22-0. Nova Techsciences lists the TESTOVA-BASE presentation at 100 mg/ml. Because no ester is attached, it requires documentation separate from esterified testosterone and Stanozolol formulations.

NOVA GAIN C

NOVA GAIN C is presented as a 650 mg/ml multi-compound injectable containing Boldenone, Nandrolone and several testosterone components. It does not have one CAS number because each active substance requires its own chemical identifier, analytical specification and safety documentation.

NOVA CUT MIX

NOVA CUT MIX is listed as a 450 mg/ml blend containing Testosterone Propionate, Trenbolone Acetate and Drostanolone Propionate. Each ingredient has a separate CAS number, contraindication profile and quality-control requirement, so the formulation should not be documented under one chemical identifier.

Letrozole

Letrozole is a non-steroidal aromatase inhibitor identified by CAS Number 112809-51-5. Nova Techsciences associates it with FEMANOVA 2.5 mg tablets. It is pharmacologically different from Stanozolol and requires separate authorised-use information, pregnancy warnings, contraindications and professional prescribing oversight.

Stanozolol ROXONOVA should ultimately be presented through correct CAS identification, transparent batch documentation, balanced safety communication and clearly stated regulatory limitations.